The estimated Net Worth of Sailaja Puttagunta is at least $736 Thousand dollars as of 1 December 2022. Sailaja Puttagunta owns over 3,365 units of BiomX Inc stock worth over $4,919 and over the last 5 years he sold PHGE stock worth over $4,442. In addition, he makes $726,485 as Chief Medical Officer at BiomX Inc.
Sign up
Sailaja Puttagunta PHGE stock SEC Form 4 insiders trading
Sailaja has made over 1 trades of the BiomX Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 3,365 units of PHGE stock worth $4,442 on 1 December 2022.
The largest trade he's ever made was selling 3,365 units of BiomX Inc stock on 1 December 2022 worth over $4,442. On average, Sailaja trades about 561 units every 0 days since 2020. As of 1 December 2022 he still owns at least 4,969 units of BiomX Inc stock.
You can see the complete history of Sailaja Puttagunta stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sailaja Puttagunta biography
Dr. Sailaja Puttagunta M.D. serves as Chief Medical Officer of the Company. Dr. Puttagunta served as the Chief Medical Officer of BiomX from December 2018 to October 2019. Prior to joining BiomX, Dr. Puttagunta served as Vice President, Development at Iterum Therapeutics plc, a clinical stage pharmaceutical company developing antibiotics against multi-drug resistant pathogens, from January 2016 to December 2018. Prior to Iterum, Dr. Puttagunta served as VP, Medical Affairs for Anti-infectives at pharmaceutical company Allergan plc from January 2015 to January 2016 and was the Vice President of Development and Medical Affairs from August 2014 to December 2014 and the Executive Director of Clinical and Medical Affairs from June 2012 through July 2014 at pharmaceutical company Durata Therapeutics, Inc., an innovative pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses, prior to its acquisition by Actavis plc. Prior to joining Durata, Dr. Puttagunta led teams within clinical development and medical affairs on various antibiotic compounds at pharmaceutical company Pfizer Inc. Dr. Puttagunta graduated from Gandhi Medical College in Hyderabad, India and completed her residency in Internal Medicine and a fellowship in Infectious Diseases at Yale University School of Medicine. She also holds an M.S. in Biochemistry from the New York University School of Medicine.
What is the salary of Sailaja Puttagunta?
As the Chief Medical Officer of BiomX Inc, the total compensation of Sailaja Puttagunta at BiomX Inc is $726,485. There are 1 executives at BiomX Inc getting paid more, with Jonathan Solomon having the highest compensation of $936,565.
How old is Sailaja Puttagunta?
Sailaja Puttagunta is 51, he's been the Chief Medical Officer of BiomX Inc since 2019. There are 6 older and 7 younger executives at BiomX Inc. The oldest executive at BiomX Inc is Alan Moses, 72, who is the Independent Director.
What's Sailaja Puttagunta's mailing address?
Sailaja's mailing address filed with the SEC is C/O ITERUM THERAPEUTICS PLC, FITZWILLIAM COURT, FL. 1, LEESON CLOSE, DUBLIN 2, L2, .
Insiders trading at BiomX Inc
Over the last 5 years, insiders at BiomX Inc have traded over $332,366 worth of BiomX Inc stock and bought 1,036,414 units worth $787,614 . The most active insiders traders include James Edeerfield Management..., Chidozie Ugwumba, and Erez Chimovits. On average, BiomX Inc executives and independent directors trade stock every 68 days with the average trade being worth of $533,749. The most recent stock trade was executed by James Edeerfield Management... on 15 July 2024, trading 11,766,000 units of PHGE stock currently worth $11,648,340.
What does BiomX Inc do?
biomx is a microbiome drug discovery company developing customized phage therapies that target and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease (ibd) and cancer. we discover and validate proprietary bacterial targets and customize our natural and engineered phage compositions against these targets. the company’s platforms use computational and synthetic biology and cutting-edge research from profs. rotem sorek, ph.d., eran elinav, m.d., ph.d., and eran segal, ph.d., of the weizmann institute of science; and professor timothy k. lu, m.d., ph.d., of the massachusetts institute of technology. investors in the company include orbimed israel incubator lp, johnson & johnson development corporation inc., takeda ventures, inc., seventure partners, mirae asset global investments, and sbi.
What does BiomX Inc's logo look like?
Complete history of Sailaja Puttagunta stock trades at Iterum Therapeutics Plc and BiomX Inc
BiomX Inc executives and stock owners
BiomX Inc executives and other stock owners filed with the SEC include:
-
Jonathan Solomon,
Chief Executive Officer, Director -
Sailaja Puttagunta,
Chief Medical Officer -
Assaf Oron,
Chief Business Officer -
Dr. Merav Bassan Ph.D.,
Chief Devel. Officer -
Russell Greig,
Independent Chairman of the Board -
Lynne Sullivan,
Independent Director -
Paul Sekhri,
Independent Director -
Alan Moses,
Independent Director -
Jonas Grossman,
Independent Director -
Gbola Amusa,
Independent Director -
Merav Bassan,
Chief Development Officer -
Marina Wolfson,
Principal Financial Officer, Vice President - Finance and Operations -
Dr. Regis A. Vilchez M.D., Ph.D.,
Sr. VP & Head of Clinical Devel. -
Dr. Inbar Gahali-Sass,
VP of Platform R&D -
Dr. Timothy K. Lu M.D., Ph.D.,
Scientific Founder -
Dr. Eran Elinav M.D., Ph.D.,
Scientific Founder -
Inbal Benjamini-Elran,
VP of HR -
Noel Kurdi,
VP of Investor Relations & Strategy -
Prof. Timothy K. Lu,
Scientific Founder -
Dr. Eran Elinav,
Scientific Founder -
Prof. Rotem Sorek Ph.D.,
Scientific Founder -
Assaf Oron,
Chief Bus. Officer -
Yaron Breski,
Director -
Erez Chimovits,
Director -
Thomas Layton Walton,
10% owner -
Eddie Williams,
Director -
Kerry Mountain Wood Llc Pro...,
-
Israel Bio Fund Gp Limited ...,
-
Chidozie Ugwumba,
-
Susan Blum,
Director -
Gregory Louis Merril,
Director -
Jonathan S Leff,
Director -
Jesse Goodman,
Director -
James Edeerfield Management...,
-
Israel Bio Fund Gp Limited ...,
-
James Edeerfield Management...,
-
Jason M. Marks,
Director -
Michael E. Dambach,
Director -
Fibrosis Foundation Cystic,